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Abstract
Background: We previously demonstrated that vascular endothelial growth factor receptor type 2
(VEGF-R2)-positive cells induced from mouse embryonic stem (ES) cells can differentiate into both
endothelial cells (ECs) and mural cells (MCs) and these vascular cells construct blood vessel structures in
vitro. Recently, we have also established a method for the large-scale expansion of ECs and MCs derived
from human ES cells. We examined the potential of vascular cells derived from human ES cells to
contribute to vascular regeneration and to provide therapeutic benefit for the ischemic brain.
Methods: Phosphate buffered saline, human peripheral blood mononuclear cells (hMNCs), ECs-, MCs-,
or the mixture of ECs and MCs derived from human ES cells were intra-arterially transplanted into mice
after transient middle cerebral artery occlusion (MCAo).
Results: Transplanted ECs were successfully incorporated into host capillaries and MCs were distributed
in the areas surrounding endothelial tubes. The cerebral blood flow and the vascular density in the
ischemic striatum on day 28 after MCAo had significantly improved in ECs-, MCs- and ECs+MCs-
transplanted mice compared to that of mice injected with saline or transplanted with hMNCs. Moreover,
compared to saline-injected or hMNC-transplanted mice, significant reduction of the infarct volume and
of apoptosis as well as acceleration of neurological recovery were observed on day 28 after MCAo in the
cell mixture-transplanted mice.
Conclusion: Transplantation of ECs and MCs derived from undifferentiated human ES cells have a
potential to contribute to therapeutic vascular regeneration and consequently reduction of infarct area
after stroke.
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Background
Stroke, for which hypertension is the most important risk
factor, is one of the common causes of death and disabil-
ity in humans. It is widely considered that stroke patients
with a higher cerebral blood vessel density show better
progress and survive longer than patients with a lower vas-
cular density. Angiogenesis, which has been considered to
the growth of new capillaries by sprouting of preexisting
vessels through proliferation and migration of mature
endothelial cells (ECs), plays a key role in neovasculariza-
tion. Various methods for therapeutic angiogenesis,
including delivery of angiogenic factor [1,2] or cell trans-
plantation [3-5], have been used to induce collateral
blood vessel development in several animal models of
cerebral ischemia. More recently, an alternative paradigm,
known as postnatal vasculogenesis, has been shown to
contribute to some forms of neovascularization. In vascu-
logenesis, endothelial progenitor cells (EPCs), which have
been recognized as cellular components of the new vessel
structure and reserved in the bone marrow, can take an
important part in tissue neovascularization after ischemia
[6]. Previous reports demonstrated that transplantation of
mouse bone marrow cells after cerebral ischemia
increased the cerebral blood flow partially via the incor-
poration of EPCs into host vascular structure as vasculo-
genesis [4]. However, because the population of EPCs in
the bone marrow and in the peripheral blood has been
revealed to be very small [7], it is now recognized to be
difficult to prepare enough EPCs for the promotion of
therapeutic vaculogenesis after ischemia.
We previously demonstrated that VEGF-R2-positive cells
induced from undifferentiated mouse embryonic stem
(ES) cells can differentiate into both VE-cadherin-positive
endothelial cells (ECs) and αSMA-positive mural cells
(MCs), and these vascular cells construct blood vessel
structures [8]. We have also succeeded that after the induc-
tion of differentiation on OP9 feeder layer, VEGFR-2-pos-
itive cells derived from not only monkey ES cells [9] but
human ES cells [10], effectively differentiated into both
ECs and MCs. Next, we demonstrated that VE-cad-
herin+VEGF-R2+TRA-1-cells differentiated from human ES
cells on day 10 of differentiation, which can be considered
as ECs in the early differentiation stage, could be
expanded on a large scale to produce enough number of
ECs for transplantation [10]. Moreover, we also succeeded
in expanding not only ECs but also MCs derived from
these ECs in the early differentiation stage in vitro.
In the present study, we examined whether ECs and MCs
derived from human ES cells could serve as a source for
vasculogenesis in order to contribute to therapeutic neo-
vascularization and to neuroprotection in the ischemic
brain.
Methods
Preparation of human ECs and/or MCs derived from 
human ES cells
Maintenance of human ES cell line (HES-3) was described
previously [10]. We plated small human ES colonies on
OP9 feeder layer to induce differentiation into ECs and
MCs [10]. On day 10 of differentiation, VE-cad-
herin+VEGF-R2+TRA-1- cells were sorted with a fluores-
cence activator cell sorter (FACSaria; Becton Dickinson).
Monoclonal antibody for VEGF-R2 was labeled with
Alexa-647 (Molecular Probes). Monoclonal antibody for
TRA1-60 (Chemicon) was labeled with Alexa-488 (Molec-
ular Probes) and anti VE-cadherin (BD Biosciecnces) anti-
body was labeled with Alexa 546 (Molecular Probes).
After sorting the VE-cadherin+VEGFR-2+TRA-1- cells on
day 10 of differentiation, we cultured them on type IV col-
lagen-coated dishes (Becton Dickinson) with MEM in the
presence of 10% fetal calf serum (FCS) and 50 ng/ml
human VEGF165 (Peprotech) and expanded these cells.
After five passages in culture (= approximately 30 days
after the sorting), we obtained the expanded cells as a mix-
ture of ECs and MCs derived from human ES cells (hES-
ECs+MCs). The cell mixture was composed of almost the
same number of ECs and MCs. We resorted the VE-cad-
herin+ cells from these expanded cells to obtain ECs for
transplantation (Figure 1). The ECs derived from human
ES cells (hES-ECs) were labeled with CM-Dil (Molecular
Probes) before the transplantation.
Schematic representation of preparation of the transplanted  vascular cells differentiated from human ES cells Figure 1
Schematic representation of preparation of the 
transplanted vascular cells differentiated from 
human ES cells.
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After sorting VE-cadherin-VEGFR-2+TRA-1- cells on day 8
of differentiation, we cultured these cells on type IV colla-
gen-coated dishes by five passages (= approximately 40
days after the sorting) in the presence of 1% FCS and
PDGF-BB (10 ng/ml) (PeproTech) to obtain only MCs
derived from human ES cells (hES-MCs) for the transplan-
tation (Figure 1). On the day of transplantation, these
cells were washed with PBS twice and harvested with
0.05% trypsin and 0.53 mmol/L EDTA (GIBCO) for 5
minutes. Each cells used for the transplantation was sus-
pended in 50 ul PBS.
Preparation of human mononuclear cells
We performed the transplantation of human mononu-
clear cells (hMNCs), which contain a very small popula-
tion of EPCs ( 0.02%) [7], to examine the non-specific
influences due to the cell transplantation itself. The
hMNCs were prepared from 10 ml samples of peripheral
blood of healthy volunteers. Each sample was diluted
twice with PBS and layered over 8 ml of Ficoll (Bio-
sciences). After centrifugation at 2500 g for 30 minutes,
the mononuclear cell layer was harvested in the interface
and resuspended in PBS (3 × 106 cells/50 ul) for the trans-
plantation.
Immunohistochemical examination of cultured cells
Staining of cultured cells on dishes at 5th passage was per-
formed as described elsewhere [8,10]. Monoclonal anti-
bodies for alpha smooth muscle actin (αSMA) (Sigma),
human CD 31 (BD Biosciecnces) and calponin (Dako
Cytomation) were used.
Middle cerebral artery occlusion (MCAo) model and cell 
transplantation
We used adult male C57 BL6/J mice weighing 20–25 g for
all our experiments, and all of them were anesthetized
with 5% halothane and maintained 1% during the exper-
iments. We induced transient left middle cerebral artery
occlusion (MCAo) for 20 min as previously described
[11]. Briefly, a 8-0 nylon monofilament coated with sili-
cone was inserted from the left common carotid artery
(CCA) via the internal carotid artery to the base of the left
MCA. After the occlusion for 20 minutes, the filament was
withdrawn and intra-arterial injection of hES-derived vas-
cular cells was performed through the left CCA. We pre-
pared four groups of the transplanted cells; Group1: PBS
(50 ul), Group 2: hMNCs (3 × 106 cells), Group 3: hES-
ECs (1.5 × 106 cells), Group 4: hES-MCs (1.5 × 106 cells),
Group 5: hES-ECs+MCs (3 × 106 cells). After transplanta-
tion, the distal portion of CCA was ligated. All animals
were immunosuppressed with cyclosporin A (4 mg/kg, ip)
on day 1 before the transplantation, postoperative day 1–
7, 10, 14, and 21. Experimental procedures were per-
formed in accordance with Kyoto University guidelines
for animal experiments.
Assessment for cerebral blood flow after the 
transplantation
We measured the cerebral blood flow (CBF) just before
the experiments (= day 0) and on day 4 and 28 after
MCAo by mean of a Laser-Doppler perfusion imager
(LDPI, Moor Instruments Ltd.). During the measurement,
each mouse was anesthetized with halothane and the
room temperature was kept at 25–27°C. The ratio of
blood flow of the area under MCA in the ipsilateral side to
the contralateral side was calculated as previously
described [11].
Immunohistochemical examination of the ischemic 
striatum
The harvested brains were subjected to immunohisto-
chemical examination using a standard procedure as pre-
viously described [12]. In all of our examination, free-
floating 30-μm coronal sections at the level of the anterior
commisure (= the bregma) were stained and examined
with a confocal microscope (LSM5 PASCAL, Carl Zeiss).
Sections were subjected to immunohistochemical analysis
with the antibodies for human PECAM-1 (BD Biosciec-
nces, 1:100), mouse PECAM-1 (BD Bioscience, 1:100),
human HLA-A, B, C (BD Biosciecnces, 1:100), αSMA (BD
Biosciecnces, 1:100), Neu-N (Chemicon, 1:200), and sin-
gle stranded DNA (Dako Cytomation, 1:100).
In our model of MCAo, the infarct area was confined to
the striatum. The ischemic striatum at the level of the
anterior commisure from each mouse was photographed
on day 28 after MCAo. The procedure of the quantifica-
tion of vascular density was carried out as described in
Yunjuan Sun et al. [13] with slight modification. Vascular
density in the ischemic striatum was examined at ×20
magnification, by quantifying the ratio of the pixels of
human and/or mouse PECAM-1-positive cells to 512 ×
512 pixels in that field: the ratio was expressed as %area.
The number of transplanted MCs detected in the ischemic
core at ×20 magnification was calculated. To identify
localization of transplanted ECs or MCs, the fields in the
ischemic striatum were photographed at ×63 magnifica-
tion. The infarct area (mm2/field/mouse) at the level of
the bregma was defined and quantified as the lesion
where Neu-N immunoreactivity disappeared in the stria-
tum at ×5 magnification as previously described [11,14].
The measurement of infarct volumes was carried out as
described in Sakai T. et al. [14] with slight modification.
Another saline- and EC+MC-injected groups were sacri-
ficed on day 28 after MCAo. For the measurements of the
infarct volume, 5 coronal sections (approximately -1 mm,
-0.5 mm, ± 0 mm, +0.5 mm and +1 mm from the bregma)
were prepared from each mouse and each infarct area
(mm2) was measured. And then, the infarct area was
summed among slices and multiplied by slice thickness to
provide infract volume (mm3). To calculate apoptoticJournal of Translational Medicine 2008, 6:54 http://www.translational-medicine.com/content/6/1/54
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cells, the number (cells/mm2/mouse) of single stranded
DNA (ss-DNA)+ cells in one field in the ischemic core
from each mouse in the saline- or hES-ECs+MCs-injected
group was quantified at ×20 magnification on day 14 after
MCAo.
Neurological Functional test
We used the rota-rod exercise machine for the assessment
of the recovery of impaired motor function after MCAo.
This accelerating rota-rod test was carried out as described
in A.J. Hunter et al. [15] with slight modification. Each
mouse was trained up to be able to keep running on the
rotating rod over 60 seconds at 9 round per minutes
(rpm) (2th speed). After the training was completed, we
placed each mouse on the rod and changed the speed of
rotation every 10 seconds from 6 rpm (1st speed) to 30
rpm (5th speed) over the course of 50 seconds and checked
the time until the mouse fell off. The exercise time (sec-
onds) on the rota-rod for each mouse was recorded just
before the experiments (= day 0) and on day 7 and 28
after MCAo.
Analysis of mRNA expression of angiogenic factors
Cultured human aortic smooth muscle cells (hAoSMC)
(Cambrex, East Rutherford, NJ) were used for control.
Total cellular RNA was isolated from hES-MCs and
human aortic smooth muscle cells (hAoSMC) (Cambrex,
East Rutherford, NJ) with RNAeasy Mini Kit (QIAGEN
K.K., Tokyo, Japan). The mRNA expression was analyzed
with One Step RNA PCR Kit (Takara, Out, Japan). The
primers used were as follows: human vascular endothelial
growth factor (VEGF, Genbank accession No.X62568), 5'-
AGGGCAGAATCATCACGAAG-3' (forward) and 5'-
CGCTCCGTCGAACTCAATTT-3' (reverse); human basic
fibroblast growth factor (bFGF, Genbank accession
No.M27968), AGAGCGACCCTCACATCAAG (forward)
and TCGTTTCAGTGCCACATACC (reverse); human
hepatic growth factor (HGF, Genbank accession
No.X16323), 5'-AGTCTGTGACATTCCTCAGTG-3' (for-
ward) and 5'-TGAGAATCCCAACGCTGACA-3' (reverse);
human platelet-derived growth factor (PDGF-B, Genbank
accession No.X02811), 5'-GCACACGCATGACAA-
GACGGC-3' (forward) and 5'-AGGCAGGCTATGCTGA-
GAGGTCC-3' (reverse); and GAPDH (Genbank accession
No.M33197), 5'-TGCACCACCAACTGCTTAGC-3' (for-
ward) and 5'-GGCATGGACTGTGGTCATGA-3' (reverse).
Polymerase chain reactions (PCR) were performed as
described in the manufacturer's protocols.
Measurement of angiogenic factors in hES-MCs-
conditioned media
After 1 × 106 cells of hES-MC or hAoSMC were plated on
10 cm type IV collagen-coated dishes and incubated with
5 ml media (αMEM with 0.5% bovine serum) for 72
hours, the concentration of human VEGF, bFGF and HGF
were measured by SRL, Inc. (Tokyo, Japan).
Statistical analysis
All data were expressed as mean ± standard error (S.E.).
Comparison of means between two groups was per-
formed with Student's t test. When more than two groups
were compared, ANOVA was used to evaluate significant
differences among groups, and if there were confirmed,
they were further examined by means of multiple compar-
isons. Probability was considered to be statistically signif-
icant at P < 0.05.
Results
Preparation and characterization of transplanted cells 
derived from human ES cells
We induced differentiation of human ES cells in an in
vitro two-dimensional culture on OP9 stromal cell line
and examined the expression of VEGF-R2, VE-cadherin
and TRA-1 during the differentiation. While the popula-
tion of VE-cadherin+VEGF-R2+TRA-1-  cells was not
detected (< 0.5%) before day 8 of differentiation, it
emerged and accounted for about 1–2% on day10 of dif-
ferentiation (Figure 2A). As we previously reported, these
VE-cadherin+VEGF-R2+TRA-1- cells on day 10 of differen-
tiation were also positive for CD34, CD31 and eNOS [10].
Therefore, we used the term 'eEC' for these ECs in the early
differentiation stage. We sorted and expanded these eECs
in vitro. These eECs were cultured in the presence of VEGF
and 10% FCS and expanded by about 85-fold after 5 pas-
sages. The expanded cells at 5th passage were constituted
with two cell fractions. One of these cells was VE-cad-
herin+  cells (35–50%), which were positive for other
endothelial markers, including, CD31 (Figure 2B–E) and
CD34 [10], indicating that cell differentiation stage had
been retained. The other was VE-cadherin-  cells (50–
65%), which were positive for αSMA and considered to
differentiate into MCs (Figure 2D–E). We sorted the frac-
tion of VE-cadherin-VEGF-R2+TRA-1-  cells, which
appeared on day 8 of differentiation and were positive for
platelet derived growth factor receptor type β (PDGFR-β)
[10], and expanded these cells for induction to MC in the
presence of PDGF-BB and 1% FCS. At passage 5, all of the
expanded cells effectively differentiated into αSMA-posi-
tive MCs (Figure 2F–G).
Assessment of cerebral blood flow recovery in the infarct 
area after the transplantation
As shown in Figure 3B, the cerebral blood flow in the ipsi-
lateral side decreased by approximately 80% compared to
that in the contralateral side during MCAo and the area
with the suppressed blood flow was corresponded to the
area under MCA. In the 5 groups, the CBF ratio on day 4
decreased by about 20% compared to that of the contral-
ateral side due to ligation of the left CCA after the trans-Journal of Translational Medicine 2008, 6:54 http://www.translational-medicine.com/content/6/1/54
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Characterization of the transplanted vascular cells derived from human ES cells (HES-3) Figure 2
Characterization of the transplanted vascular cells derived from human ES cells (HES-3). A, Flow cytometric anal-
ysis of VE-cadherin and VEGF-R2 expression on human ES cells during differentiation on an OP9 feeder layer. VE-cad-
herin+VEGF-R2+TRA-1- cells are indicated by the boxed areas. B, Morphology of the VE-cadherin+ cells (= hES-ECs) resorted 
from expanded VE-cadherin+VEGF-R2+TRA-1- cells at 5th passage. C, Immunostaining for human PECAM-1 (brown) of hES-
ECs. D, Morphology of the expanded VE-cadherin+VEGF-R2+TRA-1- cells at 5th passage (= hES-ECs+MCs). E, Double immu-
nostaining for human PECAM-1 (brown) and αSMA (purple) on hES-ECs+MCs. F, Morphology of the cells (= hES-MCs) 
expanded from VE-cadherin-VEGF-R2+TRA-1- cells on day 10 of differentiation with PDGF-BB and 1% FCS up to 5th passage. G, 
Immunostaining for αSMA (brown) of hES-MCs. H-I, Immunostaining for αSMA (green) and calponin (red) of hAoSMCs (H) 
and hES-MCs (I). Scale bar: 50 μm.
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Effects of the transplanted vascular cells on the CBF in the ipsilateral side Figure 3
Effects of the transplanted vascular cells on the CBF in the ipsilateral side. A-C: LDPI analysis of the CBF by LDPI 
evaluated in mice with the scalp removed (A). Flowmetric analysis of the CBF in the ipsilateral side (= left side: lt) during MCA-
occlusion (B). The CBF in the ipsilateral and contralateral side in the five groups on day 4 and 28 after MCAo (C). An arrow 
indicates the lesion in the hES-EC+MC-injected group where the CBF clearly increased up to or rather than the corresponding 
area in the contralateral side. Red or white indicates higher flow than blue or green. D, Quantitative analysis of the CBF ratio 
of the ipsilateral/contralateral side just before the experiments (= day 0) and on day 4 and 28 after MCAo. * P < 0.05, † P < 
0.01.
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plantation. Then, we assessed the recovery of the CBF in
the ipsilateral side from this time point. Apparent differ-
ence in the CBF in the ipsilateral side was not observed
among the 5 groups on day 4 after MCAo. However, the
blood flow of the ipsilateral side in the hES-EC+MC-
injected group, especially pointed out by the arrow,
clearly increased up to or rather than the corresponding
area in the contralateral side on day 28 after MCAo, com-
pared to other 4 groups (Figure 3C). On day 28, the CBF
ratio of the saline- and hMNC-injected group were similar
(Figure 3D), while that of hES-EC-injected group
increased significantly compared to that of these two
groups (saline: 0.919 ± 0.010, n = 12. hMNCs: 0.925 ±
0.008, n = 15. hES-ECs: 0.952 ± 0.025, n = 7. P < 0.05).
The CBF ratio of the hES-MC-injected group (0.968 ±
0.023, n = 7. P < 0.05) increased significantly compared to
that of the saline- or hMNCs-injected groups on day 28,
while that of the hES-EC+MC-injected group (1.018 ±
0.009: n = 13) increased significantly compared to not
only that of the saline- or hMNCs-injected groups (P <
0.001), but also that of the hES-EC- or hES-MC-injected
group (P < 0.01).
Localization of transplanted vascular cells derived from 
human ES cells and the vascular density in the infarct area 
after the transplantation
In the saline- and hMNCs-injected groups, the vascular
density of host capillary quantified by mouse PECAM-1
immunoreactivity in the ischemic striatum (Figure 4B, C)
was higher than that in the non-ischemic striatum (Figure
4A). In hMNCs-injected group, few human PECAM-1 pos-
itive cells were observed in the ischemic striatum (Figure
4C) and these cells were not found in the non-ischemic
striatum. In the hES-EC-injected group, many DiI positive
hES-ECs were observed in the infarct area (Figure 4D) and
incorporated into the host capillaries (Figure 4E). In the
hES-MC-injected group, both αSMA and human HLA pos-
itive cells (23.1 ± 2.0 counts/field: n = 7) were detected in
the infarct area (Figure 4F) and localized in the conjunc-
tion with mouse endothelial tubes (Figure 4G). Compati-
ble with these results, in the hES-EC+MC-injected group,
many human PECAM-1 positive cells were detected in the
host capillaries (Figure 4H) while transplanted MCs (21.7
± 1.8 counts/field: n = 6) surrounded the capillaries in the
infarct area, similarly to those in the hES-MCs-injected
group (Figure 4I).
In the ischemic striatum, the density (%area) of human
PECAM-1 positive cells was 0.05 ± 0.01% in the hMNC-
injected group (n = 11), 0.66 ± 0.11% in the hES-EC-
injected group (n = 7, P < 0.0001 vs hMNCs) and 0.85 ±
0.12% in the hES-EC+MC-injected group (n = 11, P <
0.0001 vs hMNCs) (Figure 5A). As shown in Figure 5B,
there was no significant difference in the densities of
mouse PECAM-1 positive cells among the saline- (10.3 ±
0.4%: n = 11), hMNC- (10.9 ± 0.3%: n = 11) and hES-EC-
(11.4 ± 0.4%: n = 7) injected groups, although the densi-
ties were significantly higher than that in the non-
ischemic striatum (5.6 ± 0.2%: n = 5). In hES-MC- (13.2 ±
0.5%: n = 7, P < 0.01 vs control, P < 0.05 vs hES-ECs) or
hES-EC+MC- (13.8 ± 0.4%: n = 11, P < 0.01 vs control and
hES-ECs) injected group, a significant increase in the den-
sity of mouse PECAM-1 positive cells was observed. The
total vascular density estimated by summing up human
and mouse PECAM-1 positive area (12.2 ± 0.6%, P < 0.05)
in the hES-EC-injected group was significantly higher
compared to that in the saline-injected group. Moreover,
the total vascular density in the hES-EC+MC-injected
group (14.7 ± 0.6%) was markedly higher compared to
those in the other four groups (P < 0.001 vs control, P <
0.01 vs hES-ECs, P  < 0.05 vs hES-MCs) (Figure 5C).
Analysis of the infarct size and apoptosis in the ipsilateral 
side after the transplantation
There was no significant difference in the infarct area in
the striatum on day 28 after MCAo between the saline-
(1.372 ± 0.041 mm2: n = 10) and the hMNC- (1.438 ±
0.084 mm2: n = 10) injected groups. The infarct area in the
hES-EC- (1.308 ± 0.094 mm2: n = 6) or the hES-MC-
(1.249 ± 0.047 mm2: n = 6) injected group showed a ten-
dency to decrease. A significant decrease in the infarct area
was observed in the hES-EC+MC-injected group (1.167 ±
0.085 mm2: n = 9, P < 0.05) compared to the saline- and
hMNCs-injected groups (Figure 6A, B). We also confined
that the infarct volume was significantly reduced in the
hES-EC+MC-injected group on day 28 after MCAo, com-
pared to the saline-injected group (hES-EC+MC = 1.475 ±
0.083 mm3: n = 9, saline = 1.736 ± 0.057 mm3: n = 11, P
< 0.05) (Figure 6C). On day 14 after MCAo, the number
of ss-DNA+ cells in the ischemic penumbral area in the
hES-EC+MC-injected group (17.8 ± 2.5/mm2: n = 5, P <
0.05) significantly decreased compared to that of the
saline-injected group (43.5 ± 5.4/mm2: n = 5) (Figure 6D,
E).
Assessment of recovery of impaired motor function after 
MCAo
We estimated the exercise time by the rota-rod to evaluate
the recovery of impaired motor function. Just before the
experiment (day0) and on day 7 after MCAo, there was no
significant difference of the exercise time in the 5 groups.
Even on day 28 after MCAo, significant recovery of
impaired motor function was not detected in the hES-EC-
(31.2 ± 0.8 seconds, n = 7) or the hES-MC- (30.8 ± 0.7 sec-
onds, n = 7) injected group, compared to that of the
saline- (29.5 ± 1.2 seconds, n = 12) or hMNC- (30.1 ± 0.8
seconds, n = 15) injected group. On the other hand, we
observed the improvement in the hES-EC+MC-injected
group on day 28 after MCAo (33.1 ± 1.3 seconds, n = 13
vs saline or hMNC group: P < 0.05) (Figure 6F).Journal of Translational Medicine 2008, 6:54 http://www.translational-medicine.com/content/6/1/54
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Histological examination of the vasculature in the non-ischemic and ischemic striatum on day 28 after MCAo Figure 4 (see previous page)
Histological examination of the vasculature in the non-ischemic and ischemic striatum on day 28 after MCAo. 
A-C: Immunostaining of mouse PECAM-1 (red)/Neu-N (blue) in the non-ischemic striatum (A), and the ischemic striatum in 
saline (B)-and hMNC (C)-injected mice. Arrows show human PECAM-1+ (green) cells in the ischemic striatum in the hMNC-
injected group. D-E: Representative fluorescent photographs of the ischemic striatum stained for mouse PECAM-1 (blue), 
Neu-N (green) and CM-DiI (red) in hES-EC-injected mice. F-G: Immunostaining of αSMA (blue)/mouse PECAM-1 (green)/
human HLA-A,B,C (red) in the ischemic striatum in the hES-MC-injected mice. Human HLA positive and αSMA positive hES-
MCs were shown as purple (red+blue) cells. H, Immunostaining of mouse PECAM-1 (red)/Neu-N (blue)/human Pecam-1 
(green) in the ischemic striatum in the hES-EC+MC-injected groups. I, Localization of transplanted hES-ECs+MCs in the 
ischemic striatum stained for αSMA (blue)/mouse PECAM-1 (green)/human HLA-A,B,C (red). A-D/F/H, scale bar: 100 μm, ×20 
magnification. E/G/I, scale bar: 20 μm, ×63 magnification.
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Evaluation of vascular regeneration in the striatum on day 28 after stroke in the five groups Figure 5
Evaluation of vascular regeneration in the striatum on day 28 after stroke in the five groups. A, Quantification of 
the density of human PECAM-1+ cells (%area) in the ischemic striatum in hMNC-, hES-EC- and hES-EC+MC-injected groups. * 
P < 0.0001. B, Quantitative analysis of the density of mouse PECAM-1+ cells (%area) in the non-ischemic striatum and in the 
ischemic striatum in five groups. * P < 0.05, † P < 0.01. C, Quantification of the total density of human and mouse PECAM-1+ 
cells (%area) in the ischemic striatum in five groups. * P < 0.05, †P < 0.01, ‡ P < 0.001.
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Figure 6 (see legend on next page)
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Expression of angiogenic factors in human ES cell derived 
MCs
We investigated whether the transplanted hES-MCs pro-
duced major angiogenic factors such as VEGF, bFGF, HGF
and PDGF-BB. Reverse transcription-polymerase chain
reaction (RT-PCR) analysis detected mRNA expression of
VEGF165, VEGF189, bFGF and HGF in MCs as well as
hAoSMCs (Figure 7). In addition, we measured the pro-
tein concentration of these angiogenic factors in culture
media of hES-MCs by enzyme-linked immunosorbent
assay (ELISA). However, the concentration of all factors
did not reach the detectable level as follows; the concen-
tration of VEGF, bFGF or HGF was lower than 20 pg/ml,
10 pg/ml, or 0.3 ng/ml.
Discussion
The findings reported here demonstrate that the trans-
plantation of vascular cells, ECs and MCs derived from
human ES cells, to the ischemic brain significantly pro-
moted vascular regeneration in the infarct area and conse-
quently contributed to neurological recovery after cerebral
ischemia.
It was reported that in animal stroke models, the trans-
plantation of human bone marrow stromal cells, which
secrete basic fibroblast growth factor (bFGF) [16] and vas-
cular endothelial growth factor (VEGF) [17], activates the
endogenous expression of bFGF, VEGF and VEGFR2, and
consequently promotes endogenous angiogenesis, while
very few transplanted cells were incorporated into the
host circulation [3]. Human CD34+ cells isolated from
umbilical cord blood were found to be capable of secret-
ing several angiogenic factors, including VEGF, bFGF and
hepatocyte growth factor (HGF) [18] and administration
of these CD34+ cells after cerebral ischemia was shown to
promote endogenous angiogenesis mainly due to the sup-
ply of these angiogenic factors [5]. Bone marrow mono-
nuclear cells containing small number of EPCs
participated in neovascularization after focal cerebral
ischemia in mice [4] or patients with limb ischemia [19].
However, Rehamn et al. demonstrated that EPCs, which
were positive for acLDL and ulex-lectin, have little ability
to proliferate and could release several angiogenic growth
factors, i.e., VEGF, HGF and G-CSF [20]. Therefore, ang-
iogenic effects induced by the transplantation of EPCs
might be partially considered to be attributed to their
growth factor secretion.
In contrast, ES cells with pluripotency and self-renewal are
highlighted as a promising cell source for regeneration
medicine. We have demonstrated that ECs- and MCs-
derived from human ES cells could have a high ability of
Effects of the transplanted cells on neuroprotection and recovery of impaired motor function after MCAo Figure 6 (see previous page)
Effects of the transplanted cells on neuroprotection and recovery of impaired motor function after MCAo. A-B, 
Representative fluorescent photograph in non-ischemic and ischemic striatum. a, striatum; b, cortex; c, external capsule. The 
area where Neu-N expression was lost in the striatum in the saline-, hMNC- and hES-EC+MC-injected group represent the 
infarct areas (A) (mouse PECAM-1: red, Neu-N: blue. scale bar: 500 μm, ×5 magnification). B-C, Quantitative analysis of the 
infarct area (5 groups) in the striatum (B) and the infarct volume in the saline- and hES-EC+MC-inejcted group (C) on day 28 
after MCAo.* P < 0.05. D-E, Representative fluorescent photographs on day 14 after MCAo and quantification of ss-DNA+ cells 
in the ischemic penumbral area in the saline- and hES-EC+MC-injected group. (ss-DNA: green, Neu-N: blue. Scale bar:100 μm, 
×20 magnification. *P < 0.05). F, Assessment of recovery of impaired motor function by quantification of the time from the 
start of the exercise until collapse on an accelerating rota-rod just before the experiments (= day 0) and on day 7 and 28 after 
MCAo. * P < 0.05.
RT-PCR analysis of mRNA expression of VEGF, bFGF, HGF,  and PDGF-B in hAoSMCs and hES-MCs Figure 7
RT-PCR analysis of mRNA expression of VEGF, 
bFGF, HGF, and PDGF-B in hAoSMCs and hES-MCs. 
bp indicates base pair.
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proliferation and be successfully expanded in large scale
for the cell source of therapeutic vasculogenesis.
In the focal stroke model, endogenous angiogenesis in the
ischemic area increased partially via the promotion of the
expression of VEGF and bFGF in stroke areas [3], and in
the present study, the increase of vascular density in
saline-injected group on day 28 after MCAo was actually
observed. The finding that there was no significant differ-
ence in CBF or vascular density between saline- and
hMNCs-injected groups indicated that the effects induced
by cell transplantation itself, such as the inflammatory
reaction or embolic change, may have little or no influ-
ence on neovascularization after MCAo. Compared to the
saline- or hMNCs-injected groups, CBF in the hES-EC-
injected group increased significantly, while no significant
increase in the number of mouse PECAM-1 positive cells
was observed in the ischemic striatum on day 28 after
MCAo. So, we consider that the transplanted hES-ECs
detected in host capillaries could participate in neovascu-
larization and make a partial contribution to functional
blood vessels.
It is widely considered that during angiogenesis, the
recruitment of periendothelial cells (MCs) toward
endothelial cells sprouted from host capillaries promotes
vascular stabilization and maturation [21-23]. We there-
fore assume that the increase in endogenous angiogenesis
observed in the hES-MC-injected group in our study may
have been partially due to a reduction in the retraction of
newly-developed endothelial tubes and the promotion of
vascular maturation via adequate MC coating.
Recent report demonstrated that endothelial cells derived
from rhesus ES cells expressed von Willebrand factor
(vWF), CD146 and CD34, but not CD31 and VE-cadherin
by flow cytomerty and RT-PCR analyses [24]. Moreover,
another report suggested that the cell surface VE-cadherin-
negative populations derived during the differentiation
procedure to vascular endothelial cells in cynomolgus
monkey ES cells, which showed obvious cord-forming
capacities and a uniform acetylated low-density lipopro-
tein (Ac-LDL)-uptaking activity, expressed VE-cadherin
intracellularily. In addition, because RT-PCR analysis
demonstrated the presence of the VE-cadherin message
from the VE-cagherin-negative cells, they considered that
these cells might be 'atypical' vascular endothelial cells
[25]. Although, by reverse transcription-polymerase chain
reaction (RT-PCR) analysis, we examined the mRNA
expression of VE-cadherin in the hES-MCs to clarify
whether the cell population was consisted of pure MCs or
including 'atypical' ECs, the VE-cadherin message of the
hES-MCs was not detected [see Additional file 1]. As
shown in Figure 2H–I, the morphology of the hES-MCs
was similar to hAoSMCs and all of the hES-MCs were pos-
itive for markers of mural cells as well as hAoSMCs. In the
hES-MC-injected group, moreover, we could detect no
human HLA-positive and αSMA-negative cells in the
ischemic striatum, especially the host endothelial tubes.
Therefore, we consider that the hES-MCs used for the
transplantation were really pure MCs but not including
'atypical' ECs, and that the results observed in the hES-
MC-injected group were brought by the transplantation of
pure MCs itself.
The coordination of these beneficial effects on neovascu-
larization of hES-ECs and hES-MCs could result in the
increase in CBF and the marked promotion of vascular
density in the ischemic striatum after the transplantation
of hES-ECs+MCs. In the hES-EC+MC-injected group, the
improvement in CBF was not seen to be as remarkable as
that in the vascular density on day 28 after MCAo. Because
the blood flow under the MCA, measured in our study,
indicates the sum of both that in the ischemic striatum
and that in the non-ischemic area, such as the cerebral cor-
tex, we consider that the rate in the rise of CBF in the ipsi-
lateral side might be underestimated.
We demonstrated that in the hES-MCs, RT-PCR analysis
detected mRNA expression of some angiogenic factors,
such as VEGF, bFGF and HGF, whereas the protein con-
centration of these factors in culture media was not
enough to be detectable. Therefore, we consider that
although the secretion of these angiogenic factors might
have a possibility to affect the effect of hES-MCs trans-
plantation, adequate MC coating might be more impor-
tant for the promotion of endogenous angiogenesis after
stroke, as observed in the hES-MC- or hES-EC+MC-
injected group.
Moreover, in the hES-EC+MC-injected group, significant
reduction of apoptotic cells in the ischemic core and inf-
arct volume was observed. Even in a focal stroke model, it
was suggested that greater than 80% of newly-formed
neurons, which occurs in the subventricular zone of lat-
eral ventricule or in the dentate gyrus of the hippocampus
in the adult brain, died, most likely because of unfavora-
ble environmental condition including lack of trophic
support and exposure to toxic products from damaged tis-
sues [26,27]. Thus, we assume that the marked promotion
of neovascularization as seen in the hES-EC+MC-injected
group could provide trophic support and remove toxic
products to enhance survival of newly-formed neurons
and consequently might promote neuroprotection in the
ischemic striatum after stroke.
Conclusion
We have demonstrated that ECs and MCs could be effec-
tively differentiated from human ES cells and expanded
on a large scale. Transplantation of these vascular cellsJournal of Translational Medicine 2008, 6:54 http://www.translational-medicine.com/content/6/1/54
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markedly enhanced neovascularization in the ischemic
brain and consequently promoted neuroprotection in a
transient MCAo model. These finding suggest that vascu-
lar cells derived from human ES cells may have a potential
to be a source for therapeutic vascular regeneration after
stroke.
Abbreviations
ES cells: Embryonic stem cells; VEGF-R2: vascular
endothelial growth factor receptor type 2; ECs: endothe-
lial cells; MCs: mural cells; hMNCs: human peripheral
blood mononuclear cells; MCAo: middle cerebral artery
occlusion;  αSMA: alpha smooth muscle actin; hES-
ECs+MCs: a mixture of ECs and MCs derived from human
ES cells; hES-ECs: ECs derived from human ES cells; hES-
MCs: MCs derived from human ES cells.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
NO wrote the manuscript, performed all experiments, and
analyzed data. HI designed and revised the manuscript.
MS, KY, DT, and HT participated the maintenance of
human ES cell line (HES-3). KM participated the induc-
tion of middle cerebral artery occlusion (MCAo) in mice.
KP, YF and NT analyzed data and performed statistics. MI
and TS participated the maintenance of mice. KN
designed and edited the manuscript. All authors read and
approved the manuscript.
Additional material
Acknowledgements
The human ES cell (HES-3) was provided by ES cell International Pre Ltd, 
Singapore. This work was supported by grants from Japanese Ministry of 
Education, Culture, Sports, Science and Technology, Japanese Ministry of 
Health, Labor and Welfare, University of Kyoto 21st century COE program 
and Japan Smoking Foundation.
References
1. Kawamata T, Alexis NE, Dietrich WD, Finklestein SP: Intracisternal
basic fibroblast growth factor (bFGF) enhances behavioral
recovery following focal cerebral infarction in the rat.  J Cereb
Blood Flow Metab 1996, 16:542-547.
2. Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, Chopp M: VEGF
enhances angiogenesis and promotes blood-brain barrier
leakage in the ischemic brain.  J Clin Invest 2000, 106:829-838.
3. Chen Jieli, Zhang Zheng Gang, Li Yi, Lei Wang, Yong Xu Xian, Subhash
Gautam C, Michael Chopp: Intravenous Administration of
Human Bone Marrow Stromal Cells Induces Angiogenesis in
the Ischemic Boundary Zone After Stroke in Rat.  Circulation
research 2003, 92:692-699.
4. Zheng Zhang Gang, Li Zhang, Jiang Quan, Chopp Michael: Bone Mar-
row-Derived Endothelial Progenitor Cells Participate in
Cerebral Neovascularization After Focal Cerebral Ischemia
in the Adult Mouse.  Circulation research 2002, 90:284-288.
5. Akihiko Taguchi, Toshihiro Soma, Hidekazu Tanaka, Takayoshi Kanda,
Hiroyuki Nishimura, Tomohiro Matsuyama: Administration of
CD34+cells after stroke enhances neurogenesis via angiogen-
esis in a mouse model.  J Clin Invest 2004, 114:330-338.
6. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Asahara
T: Transplanted of ex vivo expanded endothelial progenitor
cells For therapeutic neovascularization.  Proc Natl Acad Sci USA
2000, 97:3422-3427.
7. Peichev M, Naiyer AJ, Pereira D: Expression of VEGFR-2 and
AC133 by circulating human CD34+ cells identifies a popula-
tion of functional endothelial precursors.  Blood 2000,
95:952-958.
8. Yamashita J, Itoh H, Hirashima M, Ogawa M, Nishikawa S, Yurugi T,
Naito M, Nakao K, Nishikawa S: Flk1–positive cells derived from
embryonic stem cells serve as vascular progenitors.  Nature
2000, 408:92-96.
9. Sone M, Itoh H, Yamashita J, Yurugi-Kobayashi T, Suzuki Y, Kondo Y,
Nonoguchi A, Sawada N, Yamahara K, Miyashita K, Kwijun P, Oya-
mada N, Sawada N, Nishikawa S, Nakao K: Different differentia-
tion kinetics of vascular progenitor cells in primate and
mouse embryonic stem cells.  Circulation 2003, 107:2085-2088.
10. Masakatsu Sone, Hiroshi Itoh, Kenichi Yamahara, Jun Yamashita K,
Takami Yurugi-Kobayashi, Akane Nonoguchi, Yutaka Suzuki, Ting-
Hsing Chao, Naoki Sawada, Yasutomo Fukunaga, Kazutoshi Miyashita,
Kwijun Park, Naofumi Oyamada, Naoya Sawada, Daisuke Taura, Nao-
hisa Tamura, Yasushi Kondo, Shinji Nito, Hirofumi Suemori, Norio
Nakatsuji, Sin-Ichi Nisikawa, Kazuwa Nakao: A pathway for differ-
entiation of human embryonic stem cells to vascular cell
components and their potential for vascular regeneration.
Anterioscler Thromb Vasc Biol 2007, 27:2127-34.
11. Kazutoshi Miyashita, Hiroshi Itoh, Hiroshi Arai, Takayasu Suganami,
Naoki Sawada, Yasutomo Fukunaga, Masakatsu Sone, Kenichi Yama-
hara, Takami Yurugi-Kobayashi, Kwijiun Park, Naofumi Oyamada,
Naoya Sawada, Daisuke Taura, Hirokazu Tsujimoto, Ting-Hsing
Chao, Naohisa Tamura, Masashi Mukoyama, Kazuwa Nakao: The
Neuroprotective and Vasculo-Neuro-Regenative Roles of
Adrenomedullin in Ischemic Brain and Its Therapeutic
Potential.  Endocrinology 2006, 147(4):1642-1653.
12. Teramoto T, Qui J, Plumier JC, Moskowitz MA: EGF amplifies the
replacement of parvalbumin-expressing striatal interneu-
rons after ischemia.  J Clin Invest 2003, 111:1125-1132.
13. Yunjuan Sun, Kunlin Jun, Lin Xie, Jocelyn Childs, Xiao Ou Mao, David
A: VEGF-induced neuroprotection, neurogenesis, and angio-
genesis after focal cerebral ischemia.  J Clin Invest 2003,
111:1843-1851.
14. Takao Sakai, Kamin Johnson J, Michihiro Murozono, Keiko Sakai, Marc
Magnuson A, Reinhard Fassier: Plasma fibronectin supports neu-
ronal survival and reduces brain injury following transient
focal cerebral ischemia but is not essential for skin-wound
healing and hemostasis.  Nature Medicine 2001, 7:324-330.
15. Hunter AJ, Hatcher J, Virley D, Nelson P, Irving E, Parsons AA: Func-
tional assessment in mice and rats after focal stroke.  Neurop-
harmacology 2000, 39:806-816.
Additional file 1
RT-PCR analysis of mRNA expression of VE-cadherin in hES-MCs, hES-
ECs and HUVECs. Total cellular RNA was isolated from hES-MCs, hES-
ECs and Human umbilical vein endothelial cells (HUVECs) with RNAe-
asy Mini Kit (QIAGEN K.K., Tokyo, Japan). The mRNA expression was 
analyzed with One Step RNA PCR Kit (Takara, Out, Japan). hES-ECs 
and HUVECs were used for positive controls. An initial 15-minute, 95°C 
hotstart was used, followed by cycles consisting of 1 minute denaturation 
at 94°C, 1 minute annealing, and 1 minute extension at 72°C. A 10-
minute extension was done at 72°C after the final cycle. Thirty-five cycles 
were done for VE-cadherin. Oligonucleotide primer sequences, annealing 
temperature (Ta), and predicted product size of VE-cadherin were as fol-
lows; forward: 5'-ACGGGATGACCAAGTACAGC-3', reverse: 5'-
ACACACTTTGGGCTGGTAGG-3', Ta: 58°C, product size: 597 base 
pair. mRNA expression of VE-cadherin was detected in the hES-ECs or 
HUVECs, but not in the hES-MCs.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1479-
5876-6-54-S1.pdf]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Translational Medicine 2008, 6:54 http://www.translational-medicine.com/content/6/1/54
Page 14 of 14
(page number not for citation purposes)
16. Hamano K, Li TS, Kobayashi T, Kobayashi S, Matsuzaki M, Esato K:
Angiogenesis induced by the implantation of self-bone mar-
row cells:a new material for therapeutic angiogenesis.  Cell
Trans 2000, 9:439-443.
17. Brunner G, Nguyen H, Gabrilove J, Rifkin DB, Wilson EL: Basic
fibroblast growth factor expression in human bone marrow
and peripheral blood cells.  Blood 1993, 81:631-638.
18. Marcin Majka, Anna Janowska-Wieczorek, Janina Ratajczak, Karen
Ehrenman, Zbigniew Pietrzkowski, Mariusz Ratajczak Z: Numerous
growth factors, cytokines, and chemokines are secreted by
human CD34+ cells, myeloblasts, erythroblasts, and meg-
akaryoblasts and regurate normal hematopoiesis in an auto-
crine/paracrine manner.  Blood 2001, 97:3075-3085.
19. Eriko Tateishi-Yuyama, Hiroaki Matsubara, Toyoaki Murohara, Uichi
Ikeda, Satoshi Shintani, Tsutomu Imaizumi: Therapeutic angiogen-
esis for patients with limb ischaemia by autologous trans-
plantation of bone-marrow cells: a pilot study and a
randomised controlled trial.  Lancet 2002, 360:427-435.
20. Rehman J, Li J, Orschell CM, March KL: Peripheral blood
"endothelial progenitor cells" are derived from monocyte/
macrophages and secrete angiogenic growth factors.  Circula-
tion 2003, 107:1164-1169.
21. Asahara Takayuki, Chen Donghui, Takahashi Tomono, Fujikawa
Koshi, Kearney Marianne, Jeffrey Isner M: Tie2 Receptor Ligands,
Angiopoietin-1 and Angiopoietin-2, Modulate VEGF-Induced
Postnatal Neovascularization.  Circulation Research 1998,
83:233-240.
22. Risaw W: Mechanism of angiogenesis.  Nature 1997,
386:671-674.
23. Diane Darland C, Patricia D'Amore A: Blood vessel maturation:
vascular development comes of age.  The Journal of Clinical Inves-
tigation 1999, 103:157-158.
24. Dan Kaufman S, Rachel Lewis L, Eric Hanson T, Robert Auerbach,
Johanna Plendl, James Thomson A: Functional endothelial cells
derived from rhesus monkey embryonic stem cells.  Blood
2004, 103:1325-1332.
25. Saeki K, Yoshiko Y, Nakahara M, Nakamura N, Matsuyama S, Koyan-
agi A, Yagita H, Koyanagi M, Kondo Y, You A: Highly efficient and
feeder-free production of subculturable vascular endothelial
cells from primate embryonic stem cells.  Journal of Cellular Phys-
iology 2008, 217:261-280.
26. Nakatomi H, Kuriu T, Okabe S, Yamamoto S, Hatano O, Nakafuku M:
Regeneration of hippocampal pyramidal neurons after
ischemic brain injury by recruitment of endogenous neural
progenitors.  Cell 2002, 110:429-441.
27. Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O: Neuronal
replacement from endogenous precursors in the adult brain
after stroke.  Nat Med 2002, 8:963-970.